The Motley Fool
17 Oct 2026, 08:44 UTC · 1h ago
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
Impact · against what's priced in
The article provides no catalyst for ABBV or ABT, as its primary arguments regarding dividend safety, debt structure, and revenue stability are already fully absorbed into current valuations. The mentions of revenue cushioning and debt composition merely confirm assumptions the market has already paid for.
- ABT+0.00
Doesn't touch the price's assumptions
- In context
The article mentions Abbott only to note the historical continuity of AbbVie's dividend increases, which does not impact Abbott's current valuation drivers.





